TCGA-95-7948-01A-11R-2187-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 42
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.370
- MYC_TARGETS_V2+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.160
- NOTCH_SIGNALING+0.150
- ADIPOGENESIS+0.140
- DNA_REPAIR+0.140
- MYC_TARGETS_V1+0.120
- PEROXISOME+0.030
- UV_RESPONSE_UP+0.030
- HEME_METABOLISM+0.010
Top 10 suppressed
- G2M_CHECKPOINT-0.450
- ALLOGRAFT_REJECTION-0.410
- E2F_TARGETS-0.410
- IL6_JAK_STAT3_SIGNALING-0.390
- INFLAMMATORY_RESPONSE-0.390
- MITOTIC_SPINDLE-0.380
- COMPLEMENT-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- IL2_STAT5_SIGNALING-0.370
- TNFA_SIGNALING_VIA_NFKB-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-21-1078-01A-01R-0692-07 | — | cohortSQ1 | 0.872 |
| 2 | SRR23303735 | — | — | 0.841 |
| 3 | TCGA-DK-A6B0-01A-11R-A31N-07 | — | — | 0.829 |
| 4 | DRR168599 | — | — | 0.827 |
| 5 | TCGA-GM-A2DC-01A-11R-A18M-07 | — | B | 0.822 |
| 6 | cf2834ac-00ed-4372-be25-042f38241196 | — | — | 0.813 |
| 7 | GSM5359423 | — | — | 0.813 |
| 8 | TCGA-E7-A678-01A-11R-A30C-07 | — | — | 0.811 |
| 9 | TCGA-LL-A6FP-01A-11R-A31O-07 | — | B | 0.809 |
| 10 | BS_VJVDJABP | Embryonal tumors | — | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |